Recent investigations have focused on the convergence of GLP-1|GIP|glucagon receptor activator therapies and dopaminergic communication. While GCGR stimulators are increasingly employed for managing type 2 diabetes, their potential impacts on reinforcement circuits, specifically governed by dopam